Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $9,496,316.98 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Director Bruce Booth sold 105,071 shares of the company’s stock in a transaction on Wednesday, June 17th. The stock was sold at an average price of $90.38, for a total value of $9,496,316.98. Following the sale, the director directly owned 662,042 shares in the company, valued at $59,835,355.96. This represents a 13.70% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Bruce Booth also recently made the following trade(s):

• On Monday, June 22nd, Bruce Booth sold 246,330 shares of Kymera Therapeutics stock. The shares were sold at an average price of $98.52, for a total value of $24,268,431.60.
• On Thursday, June 18th, Bruce Booth sold 115,056 shares of Kymera Therapeutics stock. The stock was sold at an average price of $91.01, for a total value of $10,471,246.56.
• On Wednesday, June 17th, Bruce Booth sold 11,741 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.98, for a total value of $1,056,455.18.
• On Monday, June 22nd, Bruce Booth sold 31,798 shares of Kymera Therapeutics stock. The shares were sold at an average price of $103.75, for a total value of $3,299,042.50.
• On Wednesday, April 22nd, Bruce Booth sold 100 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.08, for a total transaction of $9,008.00.
• On Wednesday, April 22nd, Bruce Booth sold 5,900 shares of Kymera Therapeutics stock. The shares were sold at an average price of $89.96, for a total transaction of $530,764.00.
• On Wednesday, April 15th, Bruce Booth sold 3,135 shares of Kymera Therapeutics stock. The stock was sold at an average price of $90.10, for a total transaction of $282,463.50.
• On Wednesday, April 15th, Bruce Booth sold 2,200 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.95, for a total transaction of $197,890.00.
• On Tuesday, April 14th, Bruce Booth sold 4,159 shares of Kymera Therapeutics stock. The stock was sold at an average price of $89.97, for a total value of $374,185.23.

Kymera Therapeutics Price Performance

Shares of NASDAQ KYMR traded up $9.02 during midday trading on Monday, hitting $99.45. 2,891,041 shares of the company’s stock were exchanged, compared to its average volume of 589,977. The firm’s fifty day simple moving average is $83.41 and its 200-day simple moving average is $81.31. The company has a market cap of $8.18 billion, a PE ratio of -27.86 and a beta of 2.02. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $105.00.

Kymera Therapeutics (NASDAQ:KYMR) last announced its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.89) by $0.18. The firm had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The firm’s quarterly revenue was up 55.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.82) earnings per share. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.25 EPS for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Smartleaf Asset Management LLC increased its position in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Kymera Therapeutics by 81.5% in the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after buying an additional 349 shares during the period. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Kymera Therapeutics in the 4th quarter valued at approximately $63,000. Osaic Holdings Inc. boosted its stake in shares of Kymera Therapeutics by 18,050.0% in the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares in the last quarter. Finally, PNC Financial Services Group Inc. boosted its stake in shares of Kymera Therapeutics by 56.3% in the first quarter. PNC Financial Services Group Inc. now owns 1,285 shares of the company’s stock valued at $107,000 after buying an additional 463 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research firms recently commented on KYMR. Morgan Stanley reaffirmed an “overweight” rating and issued a $119.00 target price on shares of Kymera Therapeutics in a research report on Thursday, April 30th. Stephens boosted their price target on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the company an “overweight” rating in a research report on Monday, March 2nd. Citigroup upped their price objective on shares of Kymera Therapeutics from $110.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Jefferies Financial Group started coverage on Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 target price on the stock. Finally, UBS Group boosted their target price on Kymera Therapeutics from $90.00 to $128.00 and gave the company a “buy” rating in a report on Tuesday, March 3rd. One research analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $117.14.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.